Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or
Faster, Cleaner, Better.

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)
0.8511 +0.0206 (+2.48%) 06/16/25 [NASDAQ]
0.8000 x 100 0.9004 x 100
Realtime by (Cboe BZX)
0.8000 x 100 0.9004 x 100
Realtime 0.8520 +0.0009 (-) 05:21 ET
Quote Overview for Mon, Jun 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8104
Day High
0.8565
Open 0.8300
Previous Close 0.8305 0.8305
Volume 591,900 591,900
Avg Vol 655,875 655,875
Stochastic %K 57.41% 57.41%
Weighted Alpha -28.14 -28.14
5-Day Change -0.0630 (-6.89%) -0.0630 (-6.89%)
52-Week Range 0.5526 - 1.6600 0.5526 - 1.6600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,276
  • Shares Outstanding, K 129,170
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,500 K
  • EBIT $ -28 M
  • EBITDA $ -28 M
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.71
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.20
  • Most Recent Earnings $-0.05 on 05/13/25
  • Next Earnings Date 08/11/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Options Overview Details

View History
  • Implied Volatility 125.34% ( +22.44%)
  • Historical Volatility 74.98%
  • IV Percentile 52%
  • IV Rank 23.04%
  • IV High 432.10% on 04/10/25
  • IV Low 33.52% on 09/10/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 107
  • Volume Avg (30-Day) 237
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 12,429
  • Open Int (30-Day) 11,317

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7302 +16.56%
on 05/30/25
Period Open: 0.9701
0.9900 -14.03%
on 05/20/25
-0.1190 (-12.27%)
since 05/16/25
3-Month
0.5526 +54.02%
on 04/07/25
Period Open: 0.7197
1.0700 -20.46%
on 05/14/25
+0.1314 (+18.26%)
since 03/14/25
52-Week
0.5526 +54.02%
on 04/07/25
Period Open: 1.2000
1.6600 -48.73%
on 11/11/24
-0.3489 (-29.08%)
since 06/14/24

Most Recent Stories

More News
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / May 2, 2025 / RedChip Companies will air interviews with Atossa Therapeutics, Inc. (Nasdaq:ATOS) and Ainos, Inc. (Nasdaq:AIMD) on the RedChip Small Stocks, Big Moneyâ„¢...

AIMD : 0.5036 (-0.08%)
ATOS : 0.8511 (+2.48%)
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

ATOS : 0.8511 (+2.48%)
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

ATOS : 0.8511 (+2.48%)
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

ATOS : 0.8511 (+2.48%)
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

ATOS : 0.8511 (+2.48%)
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

ATOS : 0.8511 (+2.48%)
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

ATOS : 0.8511 (+2.48%)
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

ATOS : 0.8511 (+2.48%)
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

ATOS : 0.8511 (+2.48%)
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

ATOS : 0.8511 (+2.48%)

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

3rd Resistance Point 0.9144
2nd Resistance Point 0.8854
1st Resistance Point 0.8683
Last Price 0.8511
1st Support Level 0.8222
2nd Support Level 0.7932
3rd Support Level 0.7761

See More

52-Week High 1.6600
Fibonacci 61.8% 1.2370
Fibonacci 50% 1.1063
Fibonacci 38.2% 0.9756
Last Price 0.8511
52-Week Low 0.5526

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Market Leaders Revealed: How to Spot the S&P 500's Top Performers Before the Crowd